Skye Bioscience Equity Ratio
The Equity Ratio of Skye Bioscience (SKYE) as of Oct 13, 2026 is 70.72 %. In the previous year, Equity Ratio was 93.66 % — a change of -24.49% (lower).
Get this data via API
Financial Data API
Equity Ratio
70.72 %
YoY
-24.49%
Last updated:
The Skye Bioscience Equity Ratio history
3 Years
10 Years
25 Years
Max
| YEAR | Equity Ratio | YoY |
|---|---|---|
| 70.72 % | -24.49% | |
| 93.66 % | -624.60% | |
| -17.85 % | -45.92% | |
| -33.02 % | -155.48% | |
| 59.50 % | +252.67% | |
| 16.87 % | -38.53% | |
| 27.45 % | -103.45% | |
| -795.16 % | +453.79% | |
| -143.58 % | -68.00% | |
| -448.69 % | -3,444.78% | |
| 13.41 % | -110.30% | |
| -130.20 % | — |
Skye Bioscience Stock analysis
Frequently Asked Questions about Skye Bioscience stock
Equity Ratio of Skye Bioscience is 70.72 % in 2025.
Equity Ratio of Skye Bioscience changed from 93.66 % to 70.72 %, representing a -24.49% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Equity Ratio Skye Bioscience since 2006 – with annual values, charts, and detailed analysis.
The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Skye Bioscience with sector peers and the industry average to assess whether it is attractive.
Leverage — Skye Bioscience
All Key Metrics — Skye Bioscience
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth